News | October 23, 2024
Sumitomo Corporation entered into contract with Revorf
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
Akums Drugs will undertake this development and commercialization in India
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
WHO estimates suggest that 150 million people worldwide are affected by Trachoma
Subscribe To Our Newsletter & Stay Updated
